BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 2110015)

  • 21. Regional differences in the prostanoid receptors mediating prostaglandin F2 alpha-induced contractions of cat isolated arteries.
    Nakajima M; Ueda M
    Eur J Pharmacol; 1990 Dec; 191(3):359-68. PubMed ID: 2086248
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of contraction-mediating prostanoid receptors in human hand veins: effects of the thromboxane receptor antagonists BM13,505 and AH23848.
    Arner M; Högestätt ED; Uski TK
    Acta Physiol Scand; 1991 Jan; 141(1):79-86. PubMed ID: 2053448
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thromboxane A2 receptor antagonists inhibit endothelium-dependent contractions.
    Auch-Schwelk W; Katusic ZS; Vanhoutte PM
    Hypertension; 1990 Jun; 15(6 Pt 2):699-703. PubMed ID: 2141003
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dihydropyridine agonist Bay K 8644 inhibits platelet activation by competitive antagonism of thromboxane A2-prostaglandin H2 receptor.
    Johnson GJ; Dunlop PC; Leis LA; From AH
    Circ Res; 1988 Mar; 62(3):494-505. PubMed ID: 2449295
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective impairment of endothelium-dependent relaxations by prostaglandin endoperoxide.
    Tesfamariam B
    J Hypertens; 1994 Jan; 12(1):41-7. PubMed ID: 8157943
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A common binding site for primary prostanoids in vascular smooth muscles: a definitive discrimination of the binding for thromboxane A2/prostaglandin H2 receptor agonist from its antagonist.
    Hanasaki K; Arita H
    Biochim Biophys Acta; 1989 Sep; 1013(1):28-35. PubMed ID: 2528990
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Binding of a radioiodinated agonist to thromboxane A2/prostaglandin H2 (TXA2/PGH2) receptors in guinea pig lung membranes.
    Mais DE; Saussy DL; Magee DE; Williams CM
    Adv Prostaglandin Thromboxane Leukot Res; 1991; 21A():347-50. PubMed ID: 1825567
    [No Abstract]   [Full Text] [Related]  

  • 28. Antiaggregatory effects of thromboxane receptor antagonists in vivo.
    Darius H; Lefer AM
    Thromb Res; 1985 Dec; 40(5):663-75. PubMed ID: 2935972
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of endogenous thromboxane in contractions to U46619, oxygen, 5-HT and 5-CT in the human isolated umbilical artery.
    Templeton AG; McGrath JC; Whittle MJ
    Br J Pharmacol; 1991 May; 103(1):1079-84. PubMed ID: 1878747
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets.
    Watts IS; Wharton KA; White BP; Lumley P
    Br J Pharmacol; 1991 Feb; 102(2):497-505. PubMed ID: 1826620
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Constriction of cat coronary arteries by synthetic thromboxane A2 and its antagonism.
    Smith JB; Yanagisawa A; Zipkin R; Lefer AM
    Prostaglandins; 1987 Jun; 33(6):777-82. PubMed ID: 3671730
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Irreversible inhibition of the TXA2/PGH2 receptor of human platelets by a photoaffinity ligand.
    Zehender H; Witte EC; Wolff HP; Patscheke H
    Biochem Pharmacol; 1988 Feb; 37(3):491-5. PubMed ID: 2962585
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interactions of dihydropyridine Ca2+ channel agonists with the human platelet thromboxane A2/prostaglandin H2 receptor.
    Mayeux PR; Mais DE; Halushka PV
    Eur J Pharmacol; 1991 Jan; 206(1):15-21. PubMed ID: 1712307
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostaglandin endoperoxides and thromboxane A2 activate the same receptor isoforms in human platelets.
    Vezza R; Mezzasoma AM; Venditti G; Gresele P
    Thromb Haemost; 2002 Jan; 87(1):114-21. PubMed ID: 11848439
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transient concentrations and agonist potency of PGH2 in platelet activation by endogenous arachidonate.
    Hornberger W; Patscheke H
    Eicosanoids; 1989; 2(4):241-8. PubMed ID: 2517034
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heterogeneity of prostaglandin H2/thromboxane A2 receptors: distinct subtypes mediate vascular smooth muscle contraction and platelet aggregation.
    Furci L; Fitzgerald DJ; Fitzgerald GA
    J Pharmacol Exp Ther; 1991 Jul; 258(1):74-81. PubMed ID: 1830100
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of endothelium-derived prostanoid in angiotensin-induced vasoconstriction.
    Lin L; Nasjletti A
    Hypertension; 1991 Aug; 18(2):158-64. PubMed ID: 1885223
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of thromboxane A2/prostaglandin H2 receptors of various tissues using a new radioiodinated thromboxane A2/prostaglandin H2 mimetic, I-BOP.
    Morinelli TA; Naka M; Masuda A; Oatis JE; Okwu AK; Mais DE; Saussy DL; Halushka PV
    Adv Prostaglandin Thromboxane Leukot Res; 1991; 21A():331-7. PubMed ID: 1825565
    [No Abstract]   [Full Text] [Related]  

  • 39. 15-Hydroxyeicosatetraenoic acid and diabetic endothelial dysfunction in rabbit aorta.
    Tesfamariam B; Brown ML; Cohen RA
    J Cardiovasc Pharmacol; 1995 May; 25(5):748-55. PubMed ID: 7630153
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Binding of an 125I-labeled thromboxane A2/prostaglandin H2 receptor antagonist to washed canine platelets.
    Mais DE; Kochel PJ; Saussy DL; Halushka PV
    Mol Pharmacol; 1985 Aug; 28(2):163-9. PubMed ID: 2991736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.